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Abstract Modern toxicology has embraced in vitro
methods, and major hopes are based on the Omics tech-
nologies and systems biology approaches they bring along
(Hartung and McBride in ALTEX 28(2):83–93, 2011;
Hartung et al. in ALTEX 29(2):119–28, 2012). A culture of
stringent validation has been developed for such approaches
(Leist et al. in ALTEX 27(4):309–317, 2010; ALTEX
29(4):373–88, 2012a; Toxicol Res 1:8–22, 2012b), while
the quality and usefulness of animal experiments have been
little scrutinized. A new study (Seok et al. 2013) now shows
the low predictivity of animal responses in the field of
inflammation. These findings corroborate earlier findings
from comparisons in the fields of neurodegeneration, stroke
and sepsis. The low predictivity of animal experiments in
research areas allowing direct comparisons of mouse versus
human data puts strong doubt on the usefulness of animal
data as key technology to predict human safety.
Regulatory toxicology is involved with the prediction of
human risk and with regulatory approaches to limit such
‘assumed/predicted’ risks to humans. This is a very par-
ticular form of science, in that it deals mostly not with facts
(concerning human hazard), but with assumptions and
predictions derived from models. For most compounds, the
human hazard is (fortunately!) not known. The art of pre-
dictive toxicology lies in its construction of an intricate
web of cross-relationships, to anchor the assumed human
hazard to sets of real data. Animal experiments are to date
the most important source of such data. A key question of
the discipline is: how can we get information on the
appropriateness of these data as anchor point for the toxi-
cological ‘spider net’ of cross-references and extrapola-
tions? ‘The proof of the pudding is the eating’, that is,
human data are needed to control the validity of the pre-
diction network.
The evaluation of whether animal experiments provide a
solid starting point for the prediction of human hazard can
follow two major lines. The first collects evidence from
cases of human poisoning. At least for some compounds,
this allows a direct comparison of effects on animals and on
man. Prominent examples of case studies that suggest poor
predictivity are the experience with thalidomide, or with the
TG1412 drug candidate, which caused terrible effects in
man that had not been predicted from the available animal
data (Stebbings et al. 2007). Lack of correlation is also seen
the other way around, that is, when rodent data predict
cancer for compounds that are safe in man (Gold et al. 2005;
Basketter et al. 2012). For some compound classes, there
are also positive examples of animal data quantitatively
predicting toxicity. However, in many areas of toxicology
(for instance in the field of pesticides) such comparative
data are hardly available. Moreover, this inductive approach
(using individual case studies) does not allow conclusive
general statements on the usefulness of animal experiments.
Therefore, as a second line, deductive strategies to approach
the question have been devised. Such approaches require
answers to two types of question. For instance: (a) is there at
least one field in which high-quality comparative data can
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be obtained? (b) can one show, or reasonably assume, that
the predictivity of animals for man does not differ funda-
mentally in different fields of biomedical research? If
answers to these questions can be obtained, a third step
would be the combination of the answers for deduction of a
generalized conclusion.
We will deal here with the second question only briefly.
The answer from screening the scientific literature must be
clearly ‘yes’. Tens of thousands of publications, all peer-
reviewed, often in high-impact journals, are based on the
assumption that animals are predictive of man in all the
different research areas of animal use. Comparative claims
that one area is particularly well or particularly badly pre-
dicted cannot be substantiated by the available scientific
literature. Huge amounts of public money are spent on the
assumption that animals are useful for all biomedical areas.
No granting agency has ever declared a particular field of
medical research to be pointless for animal-based research.
Animals are applied uniformly as model in all areas of
pharmacology, toxicology and general research in disease
biology. This use is endorsed by committees of scientific
experts, by ethical review boards, by the funding agencies
and by political decision makers that channel the huge sums
for funding of research and development into the different
areas. The increasing use of animals for research in the last
years has been accelerated by the widespread generation of
transgenic mice. The increase in animal experimentation in
most biomedical areas has overcompensated all successful
efforts to substitute animals in some research fields
(Hartung and Leist 2008; Blaauboer et al. 2012; Leist et al.
2012a; Hasiwa et al. 2011). The hard evidence for the belief
in the usefulness of animal experimentation across fields (in
terms of hundreds of millions of dollars and euros invested
on basis of this assumption) is overwhelming.
This also relates to the field of toxicology, which cannot
be separated from other biomedical research areas, as far as
biological mechanisms and their correlation in man and
animals are concerned (Leist et al. 2008a; Hartung 2009).
Toxicology has profited a lot from findings and methods of
other fields, and it is generally assumed that biochemical
and physiological regulations, as well as their pathological
counterparts discovered by different medical disciplines,
do also apply to the field of safety sciences (Leist et al.
2008b; Rossini and Hartung 2012). We can thus safely
assume that the predictivity of animal models is judged to
be equally high in pharmacology and toxicology, and the
following part will concentrate on where to find good
comparative data of animals versus man.
An answer has been provided by a recent noteworthy
study of Seok et al. (2013) from the ‘large scale collabo-
rative research program on inflammation and the host
response to injury’. They chose inflammation as a field of
medical research, in which human data are available and in
which the mouse models seem to have a very good
mechanistic resemblance to the human disease situation.
The biological response to injury was analyzed on a
molecular level, by looking into the regulation of about
5,000 human genes relevant to inflammation and by com-
paring them to the murine counterpart responses. The result
was surprising, almost shocking: the correlation was not
only poor, it was virtually absent for the main study areas:
burns, trauma, endotoxemia. When the study was expanded
to other areas, such as sepsis and infection, poor correla-
tions of human and mouse data were confirmed. Thus,
responses in mice cannot predict human responses; at least
in these fields. Based on the above considerations (question
(b)), there is no reason to believe that the correlation would
be better in any other field.
It might be argued, that this is only one study, and only
one very particular and small field. In this context, it is
important to look at the reasons, why these experiments
were performed. The paper by Seok is not a stand-alone
study, but it was triggered by worrying findings of 20 years
of research, which suggested that non-predictive animal
models might be the reason for the many clinical failures of
new drugs in the field of sepsis. Sepsis is a systemic
inflammatory response and still one of the leading causes
of death on intensive stations worldwide. For this reason,
enormous resources have been devoted to basic research
into its mechanisms and to the discovery of drugs.
Countless papers appeared in top-impact journals already
in the 90 s, but translation of any animal finding into
clinics failed. Opal and Cross (1999) summarized already
then ‘It has become painfully evident that animal models
provide misleading and overly optimistic estimates of the
survival benefit of specific antisepsis drugs when compared
to clinical efficacy in actual human sepsis’. This situation
did not become better with more time for trials and opti-
mization of animal studies (Buras et al. 2005). When the
only treatment discovered by this approach, activated
C-reactive protein had to be withdrawn from the market in
2011, more than 100 additional clinical trials had been
performed, and it became evident that every single
approach that had been successful in animals had failed
(Rittirsch et al. 2007; Christaki et al. 2011). Nevertheless,
animal-based studies in this field still continue to be
financed. This somehow rings memories of how prince
Hamlet’s behavior was described by Polonius: ‘Though
this be madness, yet there is method in ‘t’.
Mice continue to be used as models, as their failure in
the past has been claimed to be not due to a general
inaptness of animal models, but rather to the poor quality,
standardization and adaptation to clinical questions of such
studies. It is in fact true that there is strong evidence for
deficits in the quality and reporting of animal studies
(Hartung 2008; Macleod and van der Worp 2010; Kilkenny
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et al. 2010; van der Worp et al. 2010; van der Worp and
Macleod 2011). On this basis, one may ask whether the
translational value (Hackam and Redelmeier 2006; Rice
2012) is high enough to justify further use.
Possibly, the poor correlation, and its connection with
the quality of animal experimentation are particular fea-
tures of research on inflammation and infection. To
examine this, it is worth taking a look at an entirely dif-
ferent research field: ischemic stroke. It shares one
important feature with inflammation research: the animal
models are thought to be conceptually very close to the
human situation. In human ischemic stroke, the blood cir-
culation is occluded and exactly the same is modeled in
animals. In endotoxemia, infection or burn injury, the
stimuli in humans and mice are exactly the same. This is a
favorable situation, compared to the fields of age-related
neurodegeneration, cardiovascular disease, type II diabetes,
asthma or cancer, which require generation of quite artifi-
cial animal models. Back to stroke: how well do the animal
models work? They work similar as in inflammation: not at
all. Apart from thrombolysis, every single neuroprotective
treatment for cerebral ischemia that has worked success-
fully in animals (over 500 have been reported (van der
Worp et al. 2010)) has failed in man. This negative state-
ment is based on large numbers of trials, comprising doz-
ens of large studies and hundreds of smaller ones (De
Keyser et al. 1999; Gladstone et al. 2002; O’Collins et al.
2006; Savitz and Fisher 2007). Also, in this field, the
failure has been attributed to the poor research standards,
and quality criteria have been defined to amend this situ-
ation. Failure of drugs, despite adherence to such criteria,
then triggered the design of new criteria (Dirnagl and
Fisher 2012; Savitz and Fisher 2007). Also, in this respect,
stroke research resembles inflammation research. The
alternative conclusion, that animal studies are inherently
not suited to predict the human situation, is considered
more rarely (Musch et al. 2006; Matthews 2008).
Before a quick generalization of the conclusions, it is
certainly prudent to take a closer look at adjacent
research areas. A field related to inflammation and
infection is the research that deals with ‘countermeasures
to biological and chemical terrorism and warfare’. This
example is highlighted here, as the department of defense
of the US sponsored a National Academy of Science
of the USA report on ‘animal models for assessing
countermeasures to bioterrorism agents’, published in
December 2011 (NRC 2011). The usefulness of animal
models was evaluated by renowned scientists, and the
conclusion of the report was that animal models would
not be useful. Instead, a recommendation was issued that
human cell-based 3D in vitro systems should be devel-
oped. This decision was taken so serious that altogether
200 Mio $ have been made available since for research in
this field (Hartung and Zurlo 2012). Scientific areas
related to the one of ischemic stroke are neurodegener-
ative diseases such as Alzheimer’s or Parkinson’s disease.
This field has seen vast investments of the private and
public sector. Dozens of neuroprotective drugs and prin-
ciples have been discovered in animals, none of them
ever worked in man.
Nevertheless, the belief that mouse research can result in
information about human disease and its treatment is still
held firmly by most scientific funding agencies. Findings on
species differences tend to be neglected, and the skewing of
the available data by a publication bias toward positive
animal findings has only recently been unraveled (Sena et al.
2010). Just to name few examples, it has been clear before the
Seok study that TLR4 signaling, a pivotal process in the
inflammatory response, is different in man and mouse
(Schmidt et al. 2010), and it is generally known that many
inflammatory mediators take very different roles in different
species. Even fundamental regulations ranging from neural
control of airways (Schlepütz et al. 2012) to the biology of
stem cells (Schnerch et al. 2010) are very different between
species. All this evidence suggests that animals are not par-
ticularly good predictors of humans, in the areas where we
have comparative data on different species. Is toxicology an
exception? At least some comparative data are available
from drugs that have been evaluated first in animals, then in
man. The largest comparative study in this area (Olson et al.
2000) finds a poor (i.e., 43 %) predictivity of rodents for
man. It is stated explicitly that this is not necessarily due to
different metabolism, but possibly due to a different biology.
Some examples for such molecular differences in toxico-
dynamics are well-known. For instance, man is about
1000-fold more sensitive to inhibition of the Na/K ATPase
by the cardiac glycoside ouabain than mice (Kent et al.
1987), and the difference in sensitivity to bacterial endotoxin
may even be in the million-fold range (Seok et al. 2013;
Hasiwa et al. 2013). Thus, there are many individual exam-
ples suggesting that humans are not simply 70-kg mice,
neither in pharmacology, nor in toxicology. The recent study
of Seok et al. (2013) has corroborated this notion, based on a
broad systematic approach. The statements of this paper have
been endorsed by renowned scientists that have themselves
relied on animal studies in the past. Their statement, on the
failure of mice to predict for man in an important area of
pharmacology, should be taken seriously—and also serve as
food for thought in toxicology.
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